Legal Opinion and Memorandum RE: DEA Registration and June 22, 2026 Deadline
April 24, 2026
On April 22, 2026, the United States Department of Justice, through the Acting Attorney General, issued a final order rescheduling two categories of marijuana from Schedule I to Schedule III under the Controlled Substances Act. These categories include (1) FDA-approved cannabis-derived drug products and (2) marijuana products produced and distributed under qualifying state medical marijuana programs, including those licensed by the Oklahoma Medical Marijuana Authority.
The order was issued pursuant to 21 U.S.C. § 811(d)(1) allowing expedited scheduling action without traditional notice-and-comment rulemaking. As a result, the rescheduling became effective immediately. This marks the first time that state-licensed cannabis activity has been formally incorporated into a federally regulated controlled substance category.
Scope of the Rescheduling Order
The order applies to all marijuana activity conducted within the scope of a valid OMMA license, including cultivation, processing, and dispensing. It also applies to marijuana extracts and naturally derived delta-9 THC produced under such licenses, as well as FDA-approved cannabis-derived medications.
The order does not apply to adult-use or recreational marijuana activity, which remains federally prohibited as a Schedule I substance. It likewise excludes unlicensed cannabis operations and synthetically derived cannabinoids. Hemp remains outside the Controlled Substances Act and is unaffected by the order.
DEA Registration Requirement and June 22 Deadline
The rescheduling order establishes a 60-day window for state-licensed operators to seek DEA registration. Operators who submit a completed application on or before June 22, 2026, may continue operating under their state licenses while the DEA processes their applications, which is expected to occur within approximately six months.
The order does not provide clear guidance for operators who fail to submit applications within this window. It remains uncertain whether such operators may continue operating solely under state law or whether federal enforcement exposure will attach during any delayed application period. Given this uncertainty, timely submission is the only legally conservative course.
Registration Process and Cost Structure
All OMMA licensees must apply for DEA registration. The applicable registration category depends on the nature of the licensee’s operations. Cultivators must register as bulk manufacturers, processors as manufacturers, and dispensaries as distributors.
Annual registration fees are $3,699/year for manufacturers and bulk manufacturers and $1,850/year for distributors.
In addition to these base fees, cultivators are subject to a $113 per kilogram administrative fee on harvested cannabis.
Additional Obligations for Cultivators
Cultivators operating under the rescheduling order are subject to federal requirements derived from the Single Convention on Narcotic Drugs, an international treaty to which the United States is a signatory. Under this framework, the DEA acts as the nominal intermediary in the purchase and sale of domestically produced cannabis.
In practice, where the cultivator and the downstream buyer are the same entity, the cultivator establishes a nominal price for the harvested crop. The DEA then executes a purchase-and-resale transaction at that same price, adding a per-kilogram administrative fee. For calendar year 2026, that fee is $113 per kilogram, calculated pursuant to 21 CFR 1318.06(a). Notably, this fee is not recoverable if delivery is rejected by the buyer, a risk that should be factored into harvest and distribution planning.
The broader operational mechanics of DEA registration for cultivators, including storage obligations and transaction procedures, are subject to implementing regulations that have not yet been finalized. Cultivators should anticipate compliance obligations in this area and monitor DEA rulemaking as guidance is issued.
Additionally, legal commentators have noted that the Single Convention includes a carveout that may exempt medicinal cannabis preparations from the exclusive-purchaser requirement. Whether that carveout applies to state-licensed cultivators under the rescheduling order remains an unresolved question that may affect the scope of this obligation.
Tax Implications: Elimination of 26 U.S.C. § 280E
The reclassification of marijuana to Schedule III eliminates the application of Internal Revenue Code § 280E for state-licensed medical marijuana operators. As a result, such operators may now deduct ordinary and necessary business expenses for federal tax purposes.
This represents a substantial financial shift, as operators were previously taxed on gross income rather than net income. However, questions remain regarding the retroactive application of this change and the treatment of businesses engaged in both medical and adult-use cannabis activity. Immediate consultation with tax professionals is strongly advised.
Ongoing Limitations and Unresolved Issues
Despite the rescheduling, significant federal limitations remain. Adult-use marijuana activity continues to be federally prohibited. Synthetic cannabinoids remain excluded from Schedule III protections. Federal banking restrictions and interstate commerce limitations are not resolved by the order.
Additionally, the rescheduling introduces a new layer of federal oversight. Operators who register with the DEA will be subject to federal compliance standards, inspections, and reporting obligations. Conversely, operators who do not register face increased enforcement exposure under the new federal framework.
Conclusion
The April 22, 2026 rescheduling order represents a fundamental shift in the legal treatment of state-licensed medical marijuana. It offers meaningful benefits, including tax relief and a path toward federal legitimacy, but imposes immediate compliance obligations and introduces new regulatory risks.
The June 22, 2026 DEA registration deadline is the most critical near-term requirement. Operators must act promptly to evaluate their eligibility, prepare applications, and assess the broader legal, financial, and operational consequences of entering the federal regulatory system. Failure to act within this window creates unnecessary exposure in an evolving and uncertain federal landscape.
Gies Law Firm, PLLC can assist with evaluating your eligibility, preparing DEA registration filings, and advising on compliance and risk exposure during this transition. To discuss your operation, call 405-281-0276 or schedule a consultation through our website.
This memorandum is provided for informational purposes only and does not constitute legal advice. Receipt of this memorandum does not establish an attorney-client relationship. Clients should consult with counsel regarding the application of these developments to their specific circumstances.
